Cooley Shortlisted Across Multiple Categories by LMG Life Sciences Americas
Palo Alto – June 30, 2025 – Cooley was shortlisted across 13 categories for multiple awards by LMG Life Sciences Americas, which recognizes the region’s most distinguished practitioners and their firms for exemplary work in life sciences legal practices throughout the US, Canada and Brazil.
The firm was shortlisted in the following practice area award categories: FDA Litigation and Enforcement Firm of the Year, Corporate Firm of the Year, Licensing and Collaboration Firm of the Year, M&A Firm of the Year and Venture Capital Firm of the Year.
Eight Cooley attorneys also were shortlisted across the following individual award categories:
- Sonia Nath for Regulatory Attorney of the Year – FDA Medical Devices
- Chad Shear for General Patent Litigator of the Year – California
- Betsy Flanagan for General Patent Litigator of the Year – Midwest
- Sanya Sukduang for General Patent Litigator of the Year – DC Metro
- Eric Greig for Regulatory Attorney of the Year – Pricing and Reimbursement
- David Peinsipp for Corporate Attorney of the Year
- Josh Seidenfeld for Venture Capital Attorney of the Year
- Jiqiang Lin for US Rising Star – Financial and Corporate
An awards ceremony will be held in New York City on September 4.
Life sciences breakthroughs happen with Cooley. The firm’s collaborative approach draws upon unparalleled life sciences sector experience to drive strategic solutions and resolve challenges.
The firm’s practitioners are versed in all aspects of life sciences technologies, delivering an unmatched combination of innovative legal guidance, deep industry knowledge and practical understanding of clients’ needs. Many of our lawyers worked as pharmaceutical marketing professionals, business consultants, financial leaders, biotech researchers and in-house counsel at life sciences companies before joining the Cooley team. The firm serves as trusted counsel to 2,500+ public and private life sciences company clients worldwide, including nearly 50% of the Nasdaq Biotechnology Index. Clients include innovative biotech and specialty pharmaceutical companies at the forefront of new technologies, including cell and gene therapies, artificial intelligence-led drug discovery and new vaccine technologies.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.